The FDA has accepted Aquestive Therapeutics’ new drug application for its Anaphylm sublingual epinephrine film for treating ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety ...

Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll ...

Revuforj is designed to treat patients with relapsed or refractory mutant NPM1 acute myeloid leukemia. The application has been assigned a real-time oncology review, which allows for a more efficient ...

The FDA plans to approve selected high-priority drug application submissions in 1 to 2 months rather than 10 to 12.

With the FDA recently rejecting a drug application that aims to help those living with Barth Syndrome, one Bay Area family is ...

The USFDA approved the abbreviated new drug application for Doxorubicin Hydrochloride Liposome injection and single-dose ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Luzerne County is seeking a new drug and alcohol administrator, according to an online posting. According to the administration, the position is open because Ryan Hogan was terminated, and no ...

FDA denies Unicycive's NDA for Oxylanthanum Carbonate due to vendor issues; company eyes quick resolution with alternate ...

The product, the iDose TR, is said to be the first long-term sustained release pharmaceutical for the treatment of glaucoma, according to the Aliso Viejo-based medical technology company.